COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,244 Articles (22,733 medRxiv, 8,511 bioRxiv)

Most recent first Previous |  Page 1753: Articles 17521-17530  | Next

Lack of lockdown, open borders, and no vaccination in sight: is Bosnia and Herzegovina a control group?
Fojnica, A., Osmanovic, A., Duzic, N., Fejzic, A., Mekic, E., Gromilic, Z., Muhovic, I., Kurtovic-Kozaric, A.
10.1101/2021.03.01.21252700 — Posted: 2021-03-03 Discussion: Onsite
Public perception of ethical issues related to COVID-19 control measures in Singapore, Hong Kong, and Malaysia: A cross-sectional survey
Voo, T. C., Ballantyne, A., Ng, C. J., Cowling, B. J., Xiao, J., Phang, K. C., Kaur, S., Jenarun, G., Kumar, V., Lim, J. M., Tun, Z. M., Wong, N. C. B., Tam, C. C.
10.1101/2021.03.01.21252710 — Posted: 2021-03-03
Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
Shinde, V., Bhikha, S., Hossain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. L. S., Moodley, D., Hanley, S., Fouche, L., Louw, C., Tameris, M., Singh, N., Goga, A., Dheda, K., Grobbelaar, C., Kruger, G., Carrim-Ganey, N., Baillie, V., de Oliveira, T., Koen, A. L., Lombaard, J. J., Mngqibisa, R., Bhorat, A. E., Benade, G., Lalloo, N., Pitsi, A., Vollgraaff, P.-L., Luabeya, A., Esmail, A., Petrick, F. G., Jose, A. O., Foulkes, S., Ahmed, K., Thombrayil, A., Fries, L., Cloney-Clark, S., Zhu, M., Bennett, C., Albert, G., Faust, E., Plested, J., Robertson, A., Neal, S., Cho, I., Glenn, G. M., Dubovsky, F., Madhi, S.
10.1101/2021.02.25.21252477 — Posted: 2021-03-03 Discussion: Onsite | Offsite
Perturbation of ACE2 structural ensembles by SARS-CoV-2 spike protein binding
Uyar, A., Dickson, A.
10.1101/2021.03.02.433608 — Posted: 2021-03-02
Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay
Riester, E., Findeisen, P., Hegel, J. K., Kabesch, M., Ambrosch, A., Rank, C. M., Langen, F., Laengin, T., Niederhauser, C.
10.1101/2021.03.02.21252203 — Posted: 2021-03-02
Cytoplasmic domain and enzymatic activity of ACE2 is not required for PI4KB dependent endocytosis entry of SARS-CoV-2 into host cells
Yang, H., Zhao, x., xun, M., Xu, L., Liu, B., Wang, H.
10.1101/2021.03.01.433503 — Posted: 2021-03-02
High Initial Titres of Anti-Spike Antibodies following SARS-CoV-2 Infection is Associated with Faster Decay Rates at Four Months Follow-Up
MENON, V., Shariff, M. A., Perez Gutierrez, V., Carreno, J. M., Yu, B., Jawed, M., Gossai, M., Valdez, E., Pillai, A. A., Venugopal, U., Kasubhai, M., Dimitrov, V., Krammer, F.
10.1101/2021.03.02.21252362 — Posted: 2021-03-02
Does Telemedicine Reduce health disparities? Longitudinal Evidence during the COVID-19 Pandemic in the US
Roghani, A., Panahi, S.
10.1101/2021.03.01.21252330 — Posted: 2021-03-02
Investigation of ventilation conditions associated with CO2 concentration changes in ultrasonographic exam room from the perspective of COVID-19 infection control
Matsubayashi, R. N., Harada, S., Tominaga, M.
10.1101/2021.03.01.21252598 — Posted: 2021-03-02
In vitro evaluation of the activity of terpenes and cannabidiol against Human Coronavirus E229
Chatow, L., Nudel, A., Nesher, I., Hayo Hemo, D., Rozenberg, P., Voropaev, H., Winkler, I., Levy, R., Kerem, Z., Yaniv, Z., Eyal, N.
10.1101/2021.03.01.433501 — Posted: 2021-03-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).